Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,907 result(s) found. Displaying page 88 of 146.
    «« First « Previous 84  85  86  87  88  89  90  91  92  Next» Last»»
    EudraCT Number: 2019-003370-35 Sponsor Protocol Number: MCT8-2019-2 Start Date*: Information not available in EudraCT
    Sponsor Name:Rare Thyroid Therapeutics International AB
    Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
    Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006158-16 Sponsor Protocol Number: UMCN-AKF08.02 Start Date*: 2009-02-13
    Sponsor Name:Radboud university medical center
    Full Title: Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
    Medical condition: HIV-infection in pregnant women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020173 10020175 HIV infection with other conditions LLT
    Population Age: Newborns, Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002176-41 Sponsor Protocol Number: 17HH4268 Start Date*: 2019-09-03
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)
    Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    20.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    20.0 100000004849 10066551 Chronic atrial fibrillation LLT
    20.0 100000004849 10071668 Permanent atrial fibrillation LLT
    22.1 100000004852 10057613 Thromboembolic stroke LLT
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001363-67 Sponsor Protocol Number: D5241C00001 Start Date*: 2019-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstru...
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002190-66 Sponsor Protocol Number: HS-19-647 Start Date*: 2019-07-12
    Sponsor Name:Camurus AB
    Full Title: A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) ES (Ongoing) GR (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002545-32 Sponsor Protocol Number: CR0002 Start Date*: 2019-11-06
    Sponsor Name:Ablative Solutions, Inc
    Full Title: A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003727-10 Sponsor Protocol Number: MO40598 Start Date*: 2019-12-16
    Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G...
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001084-71 Sponsor Protocol Number: B7981032 Start Date*: 2020-06-01
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, New York
    Full Title: A PHASE 3 OPEN LABEL, MULTI CENTER, LONG TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) HU (Completed) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003989-27 Sponsor Protocol Number: PROLONGSTEM Start Date*: Information not available in EudraCT
    Sponsor Name:Promethera Therapeutics
    Full Title: PROLONGSTEM: HepaStem Long-Term Safety Registry Registry for patients who have been administered HepaStem
    Medical condition: This study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HALPC during a previous interventional clinical study conducted by...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10021601 Inborn error of metabolism NOS LLT
    20.0 100000004871 10008954 Chronic liver disease and cirrhosis LLT
    20.1 100000004871 10049844 Acute liver failure LLT
    21.1 200000003094 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002428-33 Sponsor Protocol Number: SON-8184-1075 Start Date*: 2006-03-13
    Sponsor Name:SONUS Pharmaceuticals, Inc
    Full Title: A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER
    Medical condition: METASTATIC BREAST CANCER (MBC)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Prematurely Ended) HU (Prematurely Ended) ES (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003447-11 Sponsor Protocol Number: C-145-04 Start Date*: 2017-10-27
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
    Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000222-61 Sponsor Protocol Number: DS8201-A-U302 Start Date*: 2019-02-06
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2...
    Medical condition: Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Completed) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2014-002117-28 Sponsor Protocol Number: ACE-LY-004 Start Date*: 2015-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003148-19 Sponsor Protocol Number: INCB50465-205 Start Date*: 2018-05-15
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor.
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023129-39 Sponsor Protocol Number: MP4OX-10-TRA-205 Start Date*: 2011-03-22
    Sponsor Name:Sangart, Inc.
    Full Title: Estudio multicéntrico, aleatorizado, en doble ciego y controlado, para evaluar la seguridad y la eficacia del tratamiento con MP4OX, añadido al tratamiento habitual, en pacientes con traumatismo se...
    Medical condition: Pacientes con traumatismo severo y acidosis láctica por shock hemorrágico.//Severely injured trauma patients with lactic acidosis due to hemorrhagic shock.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050841 Hemorrhagic shock LLT
    12.1 10023676 Lactic acidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) DE (Completed) GB (Completed) NO (Completed) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000990-29 Sponsor Protocol Number: IC2011-02 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: Multinational européan trial for children with the opsoclonus myoclonus syndrome/dancing eye syndrome.
    Medical condition: Opsoclonus myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in children with and without neuroblastoma (NBpos and NBneg)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10015919 - Eye disorders 10053854 Opsoclonus myoclonus PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) IT (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000397-10 Sponsor Protocol Number: DSC/14/2357/51 Start Date*: 2017-07-31
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: Studio in aperto a lungo termine volto a valutare la sicurezza, la tollerabilità e l'efficacia di GIVINOSTAT in pazienti affetti da distrofia muscolare di Duchenne che sono stati precedentemente tr...
    Medical condition: Distrofia Muscolare di Duchenne (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000669-35 Sponsor Protocol Number: MK-3475-716 Start Date*: 2018-10-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
    Medical condition: High-risk Stage II melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-002475-34 Sponsor Protocol Number: REC0559-B-001 Start Date*: 2020-03-03
    Sponsor Name:Recordati Rare Diseases
    Full Title: Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
    Medical condition: Neurotrophic Keratitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10069732 Neurotrophic keratopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003009-24 Sponsor Protocol Number: MK-7902-001 Start Date*: 2020-03-18
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-...
    Medical condition: Advanced Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 84  85  86  87  88  89  90  91  92  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 16:32:00 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA